Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Atreca, Inc. (BCEL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.9952-0.0448 (-4.31%)
At close: 04:00PM EST
0.9800 -0.02 (-1.53%)
After hours: 04:08PM EST
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update

    SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- SAN CARLOS, Calif., November 10, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of recent developments. "The third quarter was a productiv

  • GlobeNewswire

    Atreca to Present at Upcoming Investor Conferences

    SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it will present at the following upcoming conferences: Cowen 6th Annual IO Next SummitNovember 11, 2022Fireside Chat: 2:40-3:00 am EST, November 11, 2022 Stifel Healthcare ConferenceNovember 15-16, 202

  • GlobeNewswire

    Atreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual Meeting

    SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced two poster presentations at the SITC 2022 Annual Meeting, being held November 8-12 in Boston, Massachusetts. Details are as follows: Title: Interim Clinical Update of the Phase 1b Trial of ATRC-101 as Monot

Advertisement
Advertisement